Inhibition of PARP-1 has been found to improve symptoms and reduce neurodegeneration in a number of AD models, including in Drosophila; therefore, treatment with Olaparib—a PARP-1 inhibitor—has shown neuroprotective effects through reduction in β-amyloid aggregates and enhancement in neuronal function [247] Moreover, nicotinamide, already a known PARP-1 inhibitor, may present a potential therapeutic strategy in early AD, as it enhances NAD+ levels and diminishes neuroinflammation [248]. This evidence concerns the gene PARP1 and Alzheimer disease.